Q2 2023 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2023-08-14 · accession 0000950123-23-008070
$2.24B
Reported value
10
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $1.57B | 69.9% | 12,886,743 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $198.4M | 8.85% | 33,290,018 | Common | SHARED |
| 68217N105 | — | Omega Therapeutics Inc | $163.7M | 7.30% | 29,225,579 | Common | SHARED |
| 81750R102 | MCRB1EUR | Seres Therapeutics Inc | $110.7M | 4.94% | 23,117,045 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $89.2M | 3.98% | 12,674,120 | Common | SHARED |
| 24823R105 | DNLI | Denali Therapeutics Inc | $77.3M | 3.45% | 2,619,968 | Common | SHARED |
| 82657L206 | — | Sigilon Therapeutics Inc | $18.0M | 0.80% | 797,720 | Common | SHARED |
| 299734202 | EVLO | Evelo Biosciences Inc | $8.2M | 0.37% | 2,521,369 | Common | SHARED |
| 05454B105 | — | Axcella Health Inc | $6.4M | 0.28% | 29,251,545 | Common | SHARED |
| 87184Q206 | SYRS | Syros Pharmaceuticals Inc | $3.1M | 0.14% | 993,848 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.